Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer

One year of IV Herceptin trastuzumab is the standard of care for women with HER2-positive early stage breast cancer ESBC Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness incre [...]

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer ESB [...]

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer The analyses was performed by British physicians in the E [...]